Glycotope Biotechnology and Cantargia Sign Production Agreement for Lead Product Candidate CAN04
Cantargia and Glycotope Biotechnology have announced an agreement on the production of Cantargia's proprietary monoclonal antibody CAN04. The product candidate CAN04 is directed against the target molecule IL1RAP, expressed on cancer stem cells, as well on mature cancer cells. Through the agreement, Glycotope Biotechnology will be Cantargia's production partner to obtain material for the clinical studies of CAN04 in cancer patients.
Glycotope Biotechnology will be responsible for the development and the GMP (Good Manufacturing Practices) production of CAN04. Glycotope Biotechnology will manufacture the material to be used in both future toxicology studies and clinical trials.
"The collaboration with Glycotope Biotechnology will be a cornerstone in the development of CAN04. We look forward to work with Glycotope Biotechnology", says Göran Forsberg, CEO of Cantargia.
"To bring Cantargia's lead drug candidate into clinical trials will be a great opportunity for Glycotope Biotechnology as Contract Manufacturer for innovative biopharmaceuticals", says Franzpeter Bracht, COO of Glycotope Biotechnology.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance